NEWTON, Mass.--(BUSINESS WIRE)--Pro-Pharmaceuticals, Inc. (AMEX: PRW), a biopharmaceutical company developing proprietary polysaccharide-based therapeutic compounds in the treatment of cancer and fibrosis, has requested a pre-Investigational New Drug (IND) meeting with the U.S. Food and Drug Administration (“FDA”) to define the regimen for an Oxygen-based product (EZ-646) to be used with Galactomannan-C (DAVANAT®) and Fluorouracil (5-FU) to treat all solid tumors, including new indications such as head & neck and breast cancers. The proposed meeting agenda is in direct response to current promising studies regarding the relationship between solid tumor attenuation and hypoxia.
